Stock Analysis

Walvax Biotechnology First Quarter 2024 Earnings: Misses Expectations

Simply Wall St

April 26, 2024

Walvax Biotechnology (SZSE:300142) First Quarter 2024 Results

Key Financial Results

Revenue: CN¥599.8m (down 28% from 1Q 2023).
Net income: CN¥14.1m (down 92% from 1Q 2023).
Profit margin: 2.4% (down from 21% in 1Q 2023).
EPS: CN¥0.009 (down from CN¥0.11 in 1Q 2023).

earnings-and-revenue-growth — SZSE:300142 Earnings and Revenue Growth April 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Walvax Biotechnology Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 26%. Earnings per share (EPS) also missed analyst estimates by 92%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 2.4% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Walvax Biotechnology you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Walvax Biotechnology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.